Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care.
Brain
/ pathology
Child
Class I Phosphatidylinositol 3-Kinases
/ genetics
Drug Resistant Epilepsy
/ metabolism
Epilepsy
/ genetics
Hemimegalencephaly
/ genetics
Humans
Malformations of Cortical Development
/ diagnostic imaging
Mutation
Phosphatidylinositol 3-Kinases
/ genetics
Proto-Oncogene Proteins c-akt
/ genetics
TOR Serine-Threonine Kinases
/ genetics
ddPCR
epilepsy
focal cortical dysplasia
hemimegalencephaly
mosaicism
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
29 04 2022
29 04 2022
Historique:
received:
20
07
2021
revised:
04
09
2021
accepted:
09
09
2021
pubmed:
1
4
2022
medline:
3
5
2022
entrez:
31
3
2022
Statut:
ppublish
Résumé
Focal malformations of cortical development including focal cortical dysplasia, hemimegalencephaly and megalencephaly, are a spectrum of neurodevelopmental disorders associated with brain overgrowth, cellular and architectural dysplasia, intractable epilepsy, autism and intellectual disability. Importantly, focal cortical dysplasia is the most common cause of focal intractable paediatric epilepsy. Gain and loss of function variants in the PI3K-AKT-MTOR pathway have been identified in this spectrum, with variable levels of mosaicism and tissue distribution. In this study, we performed deep molecular profiling of common PI3K-AKT-MTOR pathway variants in surgically resected tissues using droplet digital polymerase chain reaction (ddPCR), combined with analysis of key phenotype data. A total of 159 samples, including 124 brain tissue samples, were collected from 58 children with focal malformations of cortical development. We designed an ultra-sensitive and highly targeted molecular diagnostic panel using ddPCR for six mutational hotspots in three PI3K-AKT-MTOR pathway genes, namely PIK3CA (p.E542K, p.E545K, p.H1047R), AKT3 (p.E17K) and MTOR (p.S2215F, p.S2215Y). We quantified the level of mosaicism across all samples and correlated genotypes with key clinical, neuroimaging and histopathological data. Pathogenic variants were identified in 17 individuals, with an overall molecular solve rate of 29.31%. Variant allele fractions ranged from 0.14 to 22.67% across all mutation-positive samples. Our data show that pathogenic MTOR variants are mostly associated with focal cortical dysplasia, whereas pathogenic PIK3CA variants are more frequent in hemimegalencephaly. Further, the presence of one of these hotspot mutations correlated with earlier onset of epilepsy. However, levels of mosaicism did not correlate with the severity of the cortical malformation by neuroimaging or histopathology. Importantly, we could not identify these mutational hotspots in other types of surgically resected epileptic lesions (e.g. polymicrogyria or mesial temporal sclerosis) suggesting that PI3K-AKT-MTOR mutations are specifically causal in the focal cortical dysplasia-hemimegalencephaly spectrum. Finally, our data suggest that ultra-sensitive molecular profiling of the most common PI3K-AKT-MTOR mutations by targeted sequencing droplet digital polymerase chain reaction is an effective molecular approach for these disorders with a good diagnostic yield when paired with neuroimaging and histopathology.
Identifiants
pubmed: 35355055
pii: 6555860
doi: 10.1093/brain/awab376
pmc: PMC9630661
doi:
Substances chimiques
MTOR protein, human
EC 2.7.1.1
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
925-938Subventions
Organisme : NICHD NIH HHS
ID : P50 HD103524
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS092772
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) (2022). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
J Virol Methods. 2017 Aug;246:15-20
pubmed: 28414163
JCI Insight. 2016 Jun 16;1(9):
pubmed: 27631024
Brain. 2006 Feb;129(Pt 2):352-65
pubmed: 16291806
Clin Chem. 2013 Nov;59(11):1670-2
pubmed: 24003063
Neuropathol Appl Neurobiol. 2018 Feb;44(1):6-17
pubmed: 29359340
Nat Genet. 2012 Jun 24;44(8):941-5
pubmed: 22729223
JCI Insight. 2019 Nov 1;4(21):
pubmed: 31536475
Epilepsia. 2011 Jan;52(1):158-74
pubmed: 21219302
Am J Med Genet C Semin Med Genet. 2019 Dec;181(4):582-590
pubmed: 31441589
Ann Neurol. 2015 Apr;77(4):720-5
pubmed: 25599672
Biol Blood Marrow Transplant. 2018 May;24(5):1069-1078
pubmed: 29305193
JAMA Neurol. 2016 Jul 1;73(7):836-845
pubmed: 27159400
Neurol Genet. 2020 Dec 08;7(1):e540
pubmed: 33542949
Am J Med Genet C Semin Med Genet. 2014 Jun;166C(2):156-72
pubmed: 24888963
Acta Neuropathol. 2019 Dec;138(6):885-900
pubmed: 31444548
Neuropathol Appl Neurobiol. 2018 Feb;44(1):18-31
pubmed: 29359399
Brain. 2017 Oct 1;140(10):2610-2622
pubmed: 28969385
Elife. 2015 Dec 03;4:
pubmed: 26633882
Sci Rep. 2018 May 2;8(1):6944
pubmed: 29720614
Trends Immunol. 2012 May;33(5):215-23
pubmed: 22365572
Am J Med Genet A. 2018 Nov;176(11):2301-2308
pubmed: 30063105
J Clin Invest. 2018 Jun 1;128(6):2452-2458
pubmed: 29708508
Eur J Med Genet. 2018 Dec;61(12):738-740
pubmed: 29883676
Int J Oral Sci. 2013 Sep;5(3):121-9
pubmed: 23887128
Am J Med Genet. 2002 Nov 1;112(4):315-7
pubmed: 12376930
Front Oncol. 2020 Nov 13;10:579327
pubmed: 33304846
Brain. 2015 Jun;138(Pt 6):1613-28
pubmed: 25722288
Neurology. 2014 Jun 10;82(23):2101-6
pubmed: 24814846
Neurosurg Focus. 2013 Jun;34(6):E8
pubmed: 23724842
J Mol Diagn. 2015 May;17(3):265-72
pubmed: 25769900
Brain. 2009 Aug;132(Pt 8):2079-90
pubmed: 19506069
Clin Chim Acta. 2021 Feb;513:17-24
pubmed: 33301768
Pract Lab Med. 2020 Feb 03;19:e00153
pubmed: 32123717
Epilepsy Res. 2015 May;112:137-49
pubmed: 25847349
Front Neurosci. 2021 Jan 22;14:580357
pubmed: 33551717
Nat Rev Neurol. 2020 Nov;16(11):618-635
pubmed: 32895508
J Pediatr. 2015 Apr;166(4):1048-54.e1-5
pubmed: 25681199
Pediatr Radiol. 1995;25(5):387-8
pubmed: 7567275
Epilepsia. 2021 Jun;62(6):1416-1428
pubmed: 33949696
Oncotarget. 2012 May;3(5):546-58
pubmed: 22643842
Annu Rev Pathol. 2017 Jan 24;12:547-571
pubmed: 28135561
J Mol Diagn. 2016 Nov;18(6):851-863
pubmed: 27637301
Nat Genet. 2012 Jun 24;44(8):934-40
pubmed: 22729224
Science. 2012 Dec 21;338(6114):1619-22
pubmed: 23160955
Int J Mol Med. 2020 Sep;46(3):957-964
pubmed: 32705153
Expert Rev Neurother. 2021 Nov;21(11):1213-1224
pubmed: 33834938
Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):460-466
pubmed: 26808133
Methods Mol Biol. 2017;1492:95-106
pubmed: 27822858
Epilepsia. 2007;48 Suppl 2:21-32
pubmed: 17571350
Nat Biotechnol. 2003 Jun;21(6):673-8
pubmed: 12730666
Ann Diagn Pathol. 2020 Jun;46:151523
pubmed: 32325422
Sci Rep. 2016 Mar 09;6:22985
pubmed: 26957145